BIOMAT Database Logo BIOMAT Database Logo

Effects of bromocriptine in Huntington chorea. Case report. 1994

T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
Department of Neuropsychiatry, St. Marianna University, Yokohama City Seibu Hospital, Kanagawa, Japan.

1. The effects of bromocriptine (BC) on choreiform movement were compared with those of bromperidol (BP) and fluphenazine (FLZ) in a patient with Huntington disease. The patient (male, 42 years old) was treated with BP (15 mg/day, 4 weeks), FLZ (3 mg/day, 4 weeks), low dose of BC (5 mg/day, 4 weeks) and relatively high dose of BC (10 mg/day, 8 weeks). The CSF content of homovanilic acid (HVA) was assayed at last day of the each drug trial. The efficacy of the drugs was evaluated by electromyography. 2. Although BP and FLZ did not succeed to ameliorate the choreiform movement, both low dose and high dose BC showed rapid improvement of the involuntary movement. The CSF HVA concentration was 35.0 ng/ml before beginning treatment. Whereas FLZ and high dose of BC substantially increased the levels of HVA after the dosage (49.3 and 53.1 ng/ml, respectively), moderate increase of HVA (41.5 ng/ml) was observed when the low dose of BC was administered. These observations suggest that increase of CSF HVA might be necessary for clinical improvement of choreiform movement but not correlate with the degree of improvement and dopamine agonists could be useful drug for the treatment of choreiform movement which is refractory to the administration of neuroleptics.

UI MeSH Term Description Entries
D008297 Male Males
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004576 Electromyography Recording of the changes in electric potential of muscle by means of surface or needle electrodes. Electromyogram,Surface Electromyography,Electromyograms,Electromyographies,Electromyographies, Surface,Electromyography, Surface,Surface Electromyographies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006816 Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4) Huntington Chorea,Juvenile Huntington Disease,Akinetic-Rigid Variant of Huntington Disease,Chorea, Chronic Progressive Hereditary (Huntington),Chronic Progressive Hereditary Chorea (Huntington),Huntington Chronic Progressive Hereditary Chorea,Huntington Disease, Akinetic-Rigid Variant,Huntington Disease, Juvenile,Huntington Disease, Juvenile-Onset,Huntington Disease, Late Onset,Huntington's Chorea,Huntington's Disease,Juvenile-Onset Huntington Disease,Late-Onset Huntington Disease,Progressive Chorea, Chronic Hereditary (Huntington),Progressive Chorea, Hereditary, Chronic (Huntington),Akinetic Rigid Variant of Huntington Disease,Chorea, Huntington,Chorea, Huntington's,Huntington Disease, Akinetic Rigid Variant,Huntington Disease, Juvenile Onset,Huntington Disease, Late-Onset,Juvenile Onset Huntington Disease,Late Onset Huntington Disease
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
Bromocriptine in Huntington chorea.
July 1976, Archives of neurology,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Case report of Huntington chorea with delusional manifestations].
March 1982, Annales medico-psychologiques,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Huntington chorea: report of 16 cases].
June 1983, Arquivos de neuro-psiquiatria,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Juvenile Huntington chorea with persistent sexual deviance. A case report].
December 1989, Psychiatrie, Neurologie, und medizinische Psychologie,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
Huntington chorea.
January 1977, Archives of neurology,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Huntington chorea].
January 1989, Ugeskrift for laeger,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Case of juvenile form of Huntington chorea].
January 1980, Neurologia i neurochirurgia polska,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Day care treatment of a patient with Huntington chorea--a case report].
March 1996, Psychiatrische Praxis,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Lund-Huntington chorea].
January 1960, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
T Tsuneizumi, and K Anai, and A Aoba, and N Yamaguchi, and H Takagi, and T Chishima, and T Sakai, and K Negishi, and M Kamimura, and T Takeshita
[Huntington chorea in children].
February 1993, Archives francaises de pediatrie,
Copied contents to your clipboard!